Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2024 | $23.00 → $6.00 | Buy → Neutral | Goldman |
5/2/2024 | $32.00 | Buy | H.C. Wainwright |
3/25/2024 | $26.00 | Outperform | Leerink Partners |
8/8/2023 | Outperform | TD Cowen | |
8/8/2023 | $67.00 | Overweight | Piper Sandler |
8/8/2023 | $33.00 | Buy | Goldman |
8/8/2023 | $30.00 | Mkt Outperform | JMP Securities |
EFFECT - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
S-3 - Sagimet Biosciences Inc. (0001400118) (Filer)
Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously
H.C. Wainwright initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $32.00
Leerink Partners initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $26.00
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi
SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024. MASH Drug Development Summit Presentation Details: Presentation Title: Demonstrating denifanstat's differentiated approach in MASH with mechanistic and clinical dat
SAN MATEO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York at 11:00 a.m. ET / 8:00 a.m. PT on September 10, 2024; andA fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024. Webcasts of each fireside chat will be available in the Inve
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202
Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Neutral and lowers the price target from $23 to $6.
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.